MANNKIND CORP Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
MANNKIND CORP (MNKD) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $10.10 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-05
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $10.10M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $11.30M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $10.10M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $11.30M 10-Q · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |